Healthcare

Popular Topics in Healthcare

Subscribe to Updates in Healthcare

By RSS

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

GLG News by Oncologists in Private Practice in the U.S.

Articles with lock require a subscription to GLG News |

Request a free trial

August 6, 2008

Cancer Diagnosis and Treatment Among High Profile Celebrities and Public Figures
Analysis of: Recent Popular New Reports About Senator Ted Kennedy's Brain Tumor | www.cnn.com
Author: GLG Expert Contributor

Nothing fascinates the public interest and imagination more than news about prominent and famous media stars who suffer illness or disaster. This is the way things are, but perhaps, at least in the case of healthcare issues, it could be beneficial to society to discuss these cases in detail, from both...

August 5, 2008

IT'S A SHAME!
Analysis of: As Doctors Cater to Looks, Skin Patients Wait | www.nytimes.com
Author: GLG Expert Contributor

Skin care encompasses cosmetic procedures. But those cosmetic procedures should not take priority over the medical conditions - especially since dermatologists are uniquely qualified to treat them. I didn't go to medical school, a residency in medicine, and a fellowship in dermatology to...

August 1, 2008

More of the Same Crackdown on Amgen's Epo Agents
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: GLG Expert Contributor

The FDA used new power to order Amgen to change its product label for its Epo Stimulating Agents (ESAs). The new label will reflect what Medicare reimbursement guidelines have recently oulined.

July 9, 2008

This is not new news about Avastin
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Author: GLG Expert Contributor

Avastin is only one of many new targeted therapies that are expensive. It was first introduced in colon cancer and has helped to extend the survival of metastatic colon cancer from 3-6 months to 2 years. It has recently been approved for use in lung and breast cancers as well. It is in these...

July 2, 2008

Pharma may benefit from both new drugs and new uses for old drugs
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: GLG Expert Contributor

The public benefits when new uses are found for old drugs. The benefit comes more quickly as the pharma company does not need to go through as many early studies to allow the approval for the drug use. However, I believe that pharma realizes that new uses for old drugs is not the way...

June 24, 2008

Molecular Profiling for Epo Stimulating Agents: Trying to 'Stop the Bleeding'
Analysis of: New Study Probes Safety of Erythropoiesis-Stimulating Agents | www.medscape.com
Author: GLG Expert Contributor

Use of Epo Stimulating Agents (ESAs) for cancer patients have all but come to a screeching halt when a plattoon of studies came out suggesting that ESAs might actually cause more harm, notably by possibly acting as a growth factor for tumor cells. Now, reserachers are trying to determine...

June 6, 2008

Transgene's TG4010 Vaccine for Lung Ca - Add it to the List...
Analysis of: Transgene's Therapeutic Vaccine TG4010 Meets Primary Endpoint in Non-Small Cell Lung Cancer Phase IIb Trial | www.pipelinereview.com
Author: GLG Expert Contributor

Transgene's TG4010 vaccine has a fairy elegant two-gene design. It appears to add benefit to a standard chemo regimen in this good-sized, randomized Phase II study for advanced lung cancer. More mature survival data will be ready by year's end. Phase III study is being planned. ...

June 4, 2008

Antisoma's ASA404: Another Anti-Angiogenesis Agent to Watch
Analysis of: Positive data on Antisoma’s ASA404 presented at ASCO | www.pipelinereview.com
Author: GLG Expert Contributor

Adding novel biologic agents (such as ASA404) to traditional chemotherapy is a very hot trend in cancer research. The data from Antisoma's lung cancer study are certainly intriguing, but again, phase II, and retrospective.

June 3, 2008

Genentech’s Avastin Appears Safe in Early Colon Cancer
Analysis of: Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. | www.abstract.asco.org
Author: GLG Expert Contributor

While chemo plus Avastin is the standard of care for first treatment of advanced colon cancer, chemotherapy alone is used for most early colon cancer. This large study demonstrates the relative safety of adding Avastin to chemo in the early - adjuvant – setting.

June 3, 2008

Continuing Genentech's Herceptin - Confirming What We Suspected
Analysis of: Continuing Herceptin treatment prevents disease progression in women with aggressive metastatic breast cancer | www.pipelinereview.com
Author: GLG Expert Contributor

Many of us oncologists have been in the practice of continuing Herceptin (Trastuzumab) even when the breast cancer we were treating was growing while on the drug. Now, this randomized study gives data to back up that practice.

Page : 1 2 3 4 5 Next1 to 10 of 49

More GLG News in
Healthcare

GLG News: What Experts Think Is Important

Generated at 2008-09-05T17:45:16.330

GLG News by Oncologists in Private Practice in the U.S.

More GLG News inHealthcare

GLG News: What Experts Think Is Important

More GLG News in
Healthcare